Nasal polyps are small noncancerous growths in the nose or sinuses. They may cause pain or pressure in the face, runny or stuffy nose, and other symptoms or complications that may negatively ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

Nasal polyps are soft, painless growths on the lining of your nasal passages or sinuses, often resulting from chronic inflammation. While these benign growths themselves are not harmful ...

Amgen (NASDAQ:AMGN) and AstraZeneca (NASDAQ:AZN) announced Friday that their FDA-approved asthma therapy Tezspire reached ...

Topline results from a phase 3 trial show that tezepelumab statistically significantly reduced the size of nasal polyps and nasal congestion in adults with chronic rhinosinusitis with nasal polyps ...

The study's co-primary endpoints were to see the change from baseline in total endoscopic nasal polyp score at 52 weeks and the change from baseline in mean nasal obstruction score from weeks 49 ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials. The ANCHOR ...

(Alliance News) - AstraZeneca PLC on Friday said it received positive results from a trial of Tezspire as a treatment for chronic rhinosinusitis with nasal polyps.

Both trials met their co-primary endpoints of a change from baseline in total endoscopic nasal polyp score at 52 weeks and a change from baseline in mean nasal obstruction score from weeks 49 to 52.